https://moderndosing.infoSource-dated practitioner analysis.https://moderndosing.info/stories/hhs-six-peptides-2026-10/https://moderndosing.info/stories/hhs-six-peptides-2026-10/The October 30 notice resolves publication status, not drug approval. The HHS policy remains conditional, nonbinding and subject to change.https://moderndosing.info/stories/hims-peptides-plan-2026-10/https://moderndosing.info/stories/hims-peptides-plan-2026-10/The company’s October 29 communication describes a planned Peptides+ specialty and contingent future access.https://moderndosing.info/stories/state-of-peptides-2026/https://moderndosing.info/stories/state-of-peptides-2026/A first market assessment separates approved medicines, compounding, research sellers and the information economy.https://moderndosing.info/stories/year-2026-10-28-25/https://moderndosing.info/stories/year-2026-10-28-25/Lilly reported TRANSCEND-T2D-2 topline results comparing retatrutide with Ozempic in adults with type 2 diabetes over 80 weeks.https://moderndosing.info/stories/nsw-peptide-safety-2026-10/https://moderndosing.info/stories/nsw-peptide-safety-2026-10/The Australian surveillance release covers July 2025 through September 2026. Association is not causation.https://moderndosing.info/stories/year-2026-10-16-24/https://moderndosing.info/stories/year-2026-10-16-24/EMA recommended EU authorization for Foundayo and described orforglipron as a small non-peptide molecule.https://moderndosing.info/stories/year-2026-10-14-23/https://moderndosing.info/stories/year-2026-10-14-23/MHRA reported an October 14 raid involving over 12,000 pens it characterized as fake retatrutide and tirzepatide products; the release was published October 15.https://moderndosing.info/stories/year-2026-10-09-22/https://moderndosing.info/stories/year-2026-10-09-22/FDA’s GLP-1 active-ingredient alert carries an October 9 revision and describes detention and Green List provisions.https://moderndosing.info/stories/bpc157-human-evidence-2026-10/https://moderndosing.info/stories/bpc157-human-evidence-2026-10/An October systematic review found three small human studies and very-low-certainty evidence. The useful story is the design—not the promise.https://moderndosing.info/stories/year-2026-09-29-21/https://moderndosing.info/stories/year-2026-09-29-21/Lilly reported phase 3 retatrutide results over 80 weeks in adults with obesity and type 2 diabetes; it said results were presented at EASD and published in The Lancet.https://moderndosing.info/stories/triumph1-estimands-2026-09/https://moderndosing.info/stories/triumph1-estimands-2026-09/TRIUMPH-1 moved from a May sponsor topline to a September peer-reviewed report. The analysis behind a percentage changes what it means.https://moderndosing.info/stories/year-2026-09-23-20/https://moderndosing.info/stories/year-2026-09-23-20/FDA’s workshop page scheduled a September 23–24 program on generic GLP-1 characterization, manufacturing quality, bioequivalence and drug-device issues.https://moderndosing.info/stories/year-2026-09-18-19/https://moderndosing.info/stories/year-2026-09-18-19/FDA’s Empower Pharmacy letter describes inspection findings and alleged statutory violations involving compounded products.https://moderndosing.info/stories/bpc157-rotator-cuff-registration-2026-09/https://moderndosing.info/stories/bpc157-rotator-cuff-registration-2026-09/The record says not yet recruiting, estimates a 2027 start and disagrees internally about enrollment and the comparator.https://moderndosing.info/stories/research-label-intended-use-2026-08/https://moderndosing.info/stories/research-label-intended-use-2026-08/Two August FDA letters connect product claims, blends and injection-related tools. They are product-specific enforcement records, not verdicts about every peptide.https://moderndosing.info/stories/year-2026-08-12-18/https://moderndosing.info/stories/year-2026-08-12-18/Lilly announced legal and platform-related actions against online sellers marketing investigational compounds, including retatrutide.https://moderndosing.info/stories/year-2026-08-10-17/https://moderndosing.info/stories/year-2026-08-10-17/MHRA authorized Foundayo for specified weight-management and type 2 diabetes uses in the UK.https://moderndosing.info/stories/bpc157-gummy-registry-2026-08/https://moderndosing.info/stories/bpc157-gummy-registry-2026-08/A commercial-product record was first posted after its recorded conduct. It has no posted results module in this snapshot.https://moderndosing.info/stories/year-2026-07-23-16/https://moderndosing.info/stories/year-2026-07-23-16/The July PCAC briefing distinguishes free bases, acetate salts and proposed uses. FDA staff proposals are documented; committee vote outcomes remain unverified here.https://moderndosing.info/stories/year-2026-07-03-15/https://moderndosing.info/stories/year-2026-07-03-15/MHRA granted semaglutide conditional authorization for MASH in adults with moderate-to-advanced liver fibrosis.https://moderndosing.info/stories/wholesale-peptide-letter-2026-06/https://moderndosing.info/stories/wholesale-peptide-letter-2026-06/FDA’s June letter to Wholesale Peptide names Prostamax and Gonadorelin. It is a useful counterweight to a GLP-1-heavy annual archive.https://moderndosing.info/stories/year-2026-06-11-14/https://moderndosing.info/stories/year-2026-06-11-14/MHRA announced approval of oral semaglutide as a Wegovy tablet for adults meeting specified weight-management conditions.https://moderndosing.info/stories/reimagine2-glycaemic-endpoint-2026-06/https://moderndosing.info/stories/reimagine2-glycaemic-endpoint-2026-06/The peer-reviewed trial found a 0.16-percentage-point HbA1c advantage over semaglutide 2.4 mg under the efficacy estimand—not proof of every downstream benefit.https://moderndosing.info/stories/year-2026-05-22-13/https://moderndosing.info/stories/year-2026-05-22-13/EMA described a CHMP recommendation for oral Wegovy in adult weight management, citing a 307-participant, 64-week phase 3 study.https://moderndosing.info/stories/year-2026-04-30-12/https://moderndosing.info/stories/year-2026-04-30-12/FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list, citing no identified clinical need for bulk compounding by outsourcing facilities.https://moderndosing.info/stories/glp1-after-shortage-2026/https://moderndosing.info/stories/glp1-after-shortage-2026/The end of a shortage changes the legal framework for copies. It does not answer every patient-specific compounding question.https://moderndosing.info/stories/year-2026-04-01-11/https://moderndosing.info/stories/year-2026-04-01-11/FDA approved Foundayo, orforglipron, for the stated weight-management indication. It is an oral non-peptide GLP-1 agonist.https://moderndosing.info/stories/year-2026-03-31-10/https://moderndosing.info/stories/year-2026-03-31-10/FDA’s Gram Peptides warning letter describes website review and alleges that offered products were unapproved new drugs.https://moderndosing.info/stories/trial-registry-is-not-validation-2026-10/https://moderndosing.info/stories/trial-registry-is-not-validation-2026-10/Two primary registry records call themselves fictional or mock. That changes how a peptide pipeline should be counted.https://moderndosing.info/stories/year-2026-03-19-9/https://moderndosing.info/stories/year-2026-03-19-9/FDA approved semaglutide 7.2-mg injection for specified adults on March 19. The decision is not a blanket approval of compounded or investigational products.https://moderndosing.info/stories/year-2026-03-03-8/https://moderndosing.info/stories/year-2026-03-03-8/FDA announced 30 warning letters about compounded GLP-1 marketing, identifying sameness claims and branding that obscured the compounder.https://moderndosing.info/stories/redefine4-head-to-head-2026-02/https://moderndosing.info/stories/redefine4-head-to-head-2026-02/REDEFINE 4 reported 23% weight loss under its efficacy estimand but did not establish non-inferiority to tirzepatide.https://moderndosing.info/stories/year-2026-02-06-7/https://moderndosing.info/stories/year-2026-02-06-7/FDA announced intent to act against non-FDA-approved GLP-1 products and active ingredients used in mass-marketed compounded products.https://moderndosing.info/stories/year-2026-02-05-6/https://moderndosing.info/stories/year-2026-02-05-6/MHRA updated semaglutide guidance about the very rare eye condition NAION and evidence of a potential association.https://moderndosing.info/stories/year-2026-01-29-5/https://moderndosing.info/stories/year-2026-01-29-5/MHRA strengthened pancreatitis information for GLP-1 and dual GLP-1/GIP medicines, including rare necrotising and fatal cases.https://moderndosing.info/stories/year-2026-01-06-4/https://moderndosing.info/stories/year-2026-01-06-4/MHRA authorized a higher maximum Wegovy dose for adults with obesity on January 6; its explanatory story was published January 16.https://moderndosing.info/stories/year-2025-12-22-3/https://moderndosing.info/stories/year-2025-12-22-3/Drugs@FDA records the tablet application’s original approval on 22 December 2025. Product, route and later labeling changes stay distinct.https://moderndosing.info/stories/year-2025-11-25-2/https://moderndosing.info/stories/year-2025-11-25-2/Novo Nordisk reported positive phase 2 headline results in 448 people with type 2 diabetes. The randomized dose-finding study compared oral and subcutaneous amycretin with placebo over up to 36 weeks.https://moderndosing.info/stories/year-2025-11-05-1/https://moderndosing.info/stories/year-2025-11-05-1/Novo Nordisk presented four OASIS 4 analyses, including post hoc analyses and an indirect comparison. The underlying study included 307 adults without diabetes over 64 weeks.https://moderndosing.info/stories/year-2025-10-29-0/https://moderndosing.info/stories/year-2025-10-29-0/A claims-database SEPRA emulation used 1,144 propensity-matched pairs of adults with type 2 diabetes and found better glycemic control among semaglutide initiators.